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Abstract
Background: As transcatheter aortic valve implantation (TAVI) becomes more straightforward,  
a larger proportion of patients will be well enough to be discharged early. This study sought to charac-
terise the clinical features that allowed patients to be discharged early after TAVI and to evaluate the 
safety of an early discharge policy. 
Methods: All patients undergoing TAVI at the above cited center from August 2007 to March 2015 
were included in this study. Baseline characteristics, in-hospital outcomes, re-admissions and mortality 
were compared. 
Results: Three hundred thirty-seven TAVIs were performed during the study period, and 18 died 
in-hospital (18/337, 5.3%). Of the remaining patients, 56 were discharged within 3 days of the index 
procedure (‘early discharge group’ 56/319, 17.5%). There was no difference between the early discharge 
and late discharge group in terms of Valve Academic Research Consortium-2 (VARC-2) criteria out-
comes, all-cause re-admission rates and the need for permanent pacemaker implantation. Mortality at 
1 year was better among the early discharge group (3.6% vs. 15.6%, p = 0.014); a reflection of baseline 
clinical differences.
Conclusion: Early discharge of clinically selected TAVI patients is safe and appropriate. Lower logistic 
EuroSCORE, smaller delta creatinine and not developing any complications are factors associated with 
early discharge. (Cardiol J 2018; 25, 1: 14–23)
Key words: transcatheter aortic valve implantation, transcatheter aortic valve replacement, 
early discharge, Valve Academic Research Consortium-2 (VARC-2), safety, re-admissions
Introduction
Transcatheter aortic valve implantation (TAVI) 
has become the ‘standard of care’ for the treatment 
of high risk and surgically inoperable patients with 
symptomatic aortic stenosis (AS). The PARTNER 2 
[1] trial has also recently demonstrated that TAVI 
is non-inferior to surgical aortic valve replacement 
(sAVR) in the ‘intermediate risk’ group. The num-
ber of TAVIs performed world-wide is therefore 
likely to increase significantly in the near future. 
Moreover, recent years have seen impressive re-
ductions in complications of TAVI and consequent 
improvements in outcomes and survival, which 
was evident in PARTNER 2. TAVI is becoming 
a more straightforward and reproducible procedure 
and the move towards conscious sedation, smaller 
delivery systems and improvements in percutane-
ous closure techniques have allowed TAVI patients 
to mobilize soon after the procedure, facilitating 
early discharge. Early discharge of TAVI patients 
will improve cost-effectiveness; data already indi-
cate that despite greater procedural costs, TAVI is 
cost-effective compared with sAVR over a 10-year 
period, due to the greater post-procedural cost 
of sAVR [2]. In order to respond to an increasing 
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demand for TAVI and to improve the efficiency of 
our patient pathway, this research sought to study 
the factors associated with safe early discharge in 
a “real world” population after the TAVI procedure. 
Methods 
All cases analyzed were done between August 
2007 and March 2015. Each patient was selected for 
TAVI by a multidisciplinary Heart Team that con-
sisted of specialist nurses, interventional and im-
aging Cardiologists and Cardiothoracic Surgeons. 
Patients underwent pre-TAVI work up including 
trans-oesophageal echocardiography, coronary 
angiography and peripheral angiography as well 
as computed tomography (CT) aortography. The 
aortic valve annulus was sized using three-dimen-
sional (3D) trans-oesophageal echocardiography. 
This was the first centre in the United Kingdom 
to implant an Edwards Sapien valve (Edwards 
Lifesciences, Irvine, California) and, as such, it is 
the predominantly used prosthesis herein. During 
the study period, general anaesthetics had been 
the default method of anaesthesia and only 2 cases 
were performed under conscious sedation.
From 2007 to 2012, patients were routinely 
monitored on the Intensive Care Unit post-TAVI. 
Since October 2012, patients have been cared for 
on a level-two unit post-TAVI such as Coronary 
Care Unit/High Dependency Unit. Presented 
protocol mandates a minimum 24 h stay in a level 
two ward followed by a step-down to a cardiology/ 
/cardiothoracic ward (level one) with early mobili-
sation and physiotherapy. On day one or two (day of 
index procedure is day 0), patients undergo trans-
thoracic echocardiography. If clinically stable, the 
majority of patients will be considered for planned 
discharge on day two. 
Patient demographics, detailed procedural 
characteristics, hospital stay and outcomes are 
recorded prospectively on a national database and 
reported according to Valve Academic Research 
Consortium-2 (VARC-2) criteria [3]. Mortality and 
re-admission rates were obtained from local and 
national databases. Based on length of hospital stay, 
cases were classified into early discharge (≤ 3 days) 
and late discharge (> 3 days). In order to devise an 
early discharge protocol, a “safe outcome” measure 
was created: 
 — “Safe outcome at 30 days” was defined as 
absence of: 1) pacing post discharge up to 
30 days, 2) any cause re-admission up to 30 days, 
and 3) any cause mortality up to 30 days.
 — “Safe outcome at 1 year” was defined as ab-
sence of: 1) pacing post discharge up to 1 year, 
2) any cause re-admission up to 1 year, and 
3) any cause mortality up to 1 year.
Statistical analysis
Continuous variables are expressed as means 
and standard deviations. Parametric and non-
parametric tests were used based on sample size 
and normality of distribution. Categorical data are 
expressed as percentages. Univariable analysis 
using c2, Fisher exact, or t test, ANOVA and other 
non-parametric tests were used to identify differ-
ences between early and late discharge groups. 
Multiple imputations were used to replace miss-
ing data when the variable had less than 10% missing 
values. “Automatic Imputation Method” was used 
with five imputations. Pooled data were analyzed.
In order to determine the factors associated 
with early discharge, logistic regression model 
was generated. Seven variables were included in 
the model to permit for the rule of thumb of “5–9 
events per variable” [4]. The variables were chosen 
based on univariate analysis and what has already 
been published. The same model was then used 
to identify predictors of “safe outcome at 1 year”.
All analysis was done using SPSS statistical 
software (IBM Corp. Released 2013. IBM SPSS 
Statistics for Windows, Version 22.0. Armonk, NY: 
IBM Corp).
Results
From August 2007 until March 2015, 337 TAVI 
procedures were performed in the above cited 
center. Eighteen (5.4%) patients died in hospital. 
Fifty-six (56/319; 17.5%) patients were discharged 
home early (≤ 3 days post-procedure). Figure 1 
shows the number of days spent in hospital. The 
baseline characteristics of the study group are sum-
marized in Table 1. Just over half of our patients 
were male (50.2%). The mean age was 82.58 ± 6.7 
years. The mean hospital stay was 9.4 ± 9.7 days 
(mode 3 days, median 6 days). The median hospital 
stay among the early discharge group was 3 (in-
terquartile range [IQR]: 3–3) days and among late 
discharge group 7 (IQR: 5–13) days, p < 0.0001.
During the study period, the mean sheath 
size dropped significantly from 24 mm to 17 mm 
(p < 0.0001) and the percentage of trans-apical 
cases performed decreased from 51% to 17.4% 
(p < 0.0001). Moreover, the mean logistic Euro-
SCORE also dropped (22 to 15, p < 0.0001). The 
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above changes were associated with a significant 
rise in the percentage of early discharge (2% to 
32%, p < 0.0001) and a reduction in the overall 
mean hospital stay (11.4 to 7.1 days, p < 0.0001). 
Only two cases were done under conscious seda-
tion, both were performed in March 2015 and were 
discharged early. 
Patients discharged early had a lower New 
York Heart Association (NYHA) class III/IV (48% 
vs. 66%, p = 0.001), lower rates of peripheral 
vascular disease, lower baseline creatinine and 
a lower mean logistic EuroSCORE (16.7 vs. 21.7, 
p = 0.001) (Table 1). Echocardiographic features 
showed less aortic valve (AV) calcification and 
a larger AV area in the early discharge group (Table 1). 
The procedural characteristics were also differ-
ent between the two groups. Among patients dis-
charged early, the trans-apical route was used less, 
the sheath size was smaller, the duration of rapid 
pacing was shorter periprocedurally, and percuta-
neous closure devices were more frequently used 
(Table 2). Patients discharged early had a shorter 
level-two stay (0.93 vs. 1.43 days, p < 0.0001).
Adjudicated according to VARC-2 criteria, 
life-threatening bleeding and acute kidney injury 
(AKI) stage II or III were higher among late dis-
charge group at 30 days. There were no deaths 
among the early discharge group within 30 days 
of discharge and 3 (1.1%) patients died from 
the late discharge group (p = 1). Within 1 year, 
2 (3.6%) and 41 (15.6%) patients died, respectively 
(p = 0.014); Table 3 summaries outcomes accord-
ing to VARC-2 criteria. 
Moreover, patients in the early discharge 
group required less blood transfusion, and had 
lower delta creatinine (the difference between 
the highest creatinine level after the procedure 
and the level before) and a lower hemoglobin drop 
post-TAVI, a potential surrogate marker for bleed-
ing (Table 3). 
Using multivariable logistic regression, the 
following factors were associated with early dis-
charge: logistic EuroSCORE (odds ratio [OR] 
0.947, 95% confidence interval [CI] 0.912–0.983, 
p = 0.004), delta creatinine (OR 0.967, 95% CI 
0.949–0.985, p < 0.0001) and development of any 
complication as defined by an occurrence of any of 
the following — stroke, major or life threatening 
bleeding, major vascular injury, AKI stage II/III or 
the need for pacing (OR 0.174, 95% CI 0.048–0.630, 
p = 0.008). Factors such as prior pacing, NYHA class 
and bleeding did not influence early discharge in this 
heterogenous group of patients when accounting for 
other variables. Table 4 summarizes univariate and 
multivariate predictors of early discharge.
All-cause re-admission rate and the need for 
permanent pacing after discharge were also stud-
ied. In the early discharge group, only 2 patients 
required re-admission within 30 days (2/56, 3.6%) 
whilst there were 25 re-admissions among the late 
discharge group (25/263, 9.5%, p = 0.19). The early 
discharge group had 9 (16.1%) admissions between 
30 days and 12 months after discharge whilst the 
late discharge group of patients had 56 (21.3%) 
admissions during the same period (p = 0.4). 
64% and 54% of these re-admissions were car-
Figure 1. Hospital stay in days; Legend: frequency of hospital stay based on number of days.
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diovascular in origin at 30 days and 12 months, 
respectively (causes of these admissions are shown 
in Table 5). Up to 30-days post discharge, 2 (3.6%) 
patients out of 56 needed permanent pacing in the 
early discharge group but only 1 (0.4%) patient in 
the late discharge group. By 12 months, 2 (3.6%) 
more patients required permanent pacing in the 
early discharge group and 4 (1.5%) in the late 
discharge group (p = 0.56). 
“Safe outcome at 30 days and 1 year” was 
reached in 287 (90%) and 213 (67%) cases re-
spectively in the overall cohort. At 30 days, 93% 
of early discharge patients had safe outcomes vs. 
89% in the late discharge group (p = 0.62), and 
Table 1. Baseline characteristics.
Variable Overall Early discharge  
N = 56 (17.5%)
Late discharge  
N = 263 (82.5%)
P
Logistic EuroSCORE [%] 20.8 (10) 16.7 (9) 21.7 (11) 0.0001
Male 160 (50.2%) 27 (48%) 133 (49%) 0.4
Age [years] 82.58 (6.7) 81.8 (7.7) 82.75 (6.5) 0.6
Indication for TAVI:
High risk 203 (63.6%) 26 (46%) 177 (67%) 0.009
Surgical turn down 116 (36.4%) 30 (54%) 86 (33%)
CCS angina class III or IV 30 (9.4%) 2 (3.5%) 28 (10.6%) 0.2
NYHA class III or IV 201 (63%) 27 (48%) 174 (66%) 0.001
Diabetes mellitus 60 (18.8%) 10 (17.8%) 50 (19%) 0.4
Smoking 13 (4.1%) 0 13 (4.9%) 0.02
Hypertension 250 (78.4%) 43 (77%) 207 (79%) 0.3
Hyperlipidemia 180 (56.4%) 29 (52%) 151 (57%) 0.4
Creatinine [μmol/L] 108 (86) 93.8 (36) 111 (93) 0.021
eGFR [mL/min] 60 (20) 65.6 (19) 59 (20) 0.028
Previous myocardial infarction 23 (7.2%) 7 (12.5%) 16 (6%) 0.08
Pulmonary disease 90 (28.2%) 14 (5.3%) 76 (29%) 0.2
Neurological disease 46 (14.4%) 6 (11%) 40 (15%) 0.2
Carotid disease > 50% stenosis 63 (19.7%) 10 (18%) 53 (20%) 0.4
Peripheral vascular disease 78 (24.5%) 8 (14%) 70 (27%) 0.034
Extra cardiac arteriopathy 115 (36.1%) 15 (27%) 100 (38%) 0.07
Sinus rhythm 180 (56.4%) 31 (55%) 149 (57%) 0.6
Previous cardiac surgery 80 (25.1%) 12 (21%) 68 (26%) 0.3
Previous PCI 52 (16.3%) 7 (12.5%) 45 (17%) 0.2
Two or three vessel CAD 53 (17.7%) 8 (14%) 45 (17%) 0.3
Left main stem disease 10 (3.1%) 1 (2%) 9 (3.5%) 0.6
FEV1 [%] 81.25 (27) 82.32 (21) 80.7 (28) 0.6
Elective procedure 311 (97.4%) 56 (100%) 255 (97%) 0.1
QRS duration [ms] 114 (34) 123 (39) 112 (32) 0.057
Poor left ventricular function* 12 (3.8%) 4 (7%) 8 (3%) 0.4
Mixed aortic valve pathology 4 (1.3%) 2 (3.5%) 2 (0.8%) 0.3
Degenerative aortic valve etiology 297 (93.1%) 52 (93%) 245 (93%) 0.9
Extensive calcification of aortic valve 88 (27.6%) 7 (12.5%) 81 (31%) 0.003
Mean aortic gradient [mm Hg] 44 (15) 40 (14) 44 (14) 0.8
Peak aortic gradient [mm Hg] 77 (24 72 (25) 78 (23) 0.1
Aortic valve area [cm2] 0.82 (0.4) 0.93 (0.3) 0.8 (0.4) 0.008
*Ejection fraction < 30%; CAD — coronary artery disease; CCS — Canadian Cardiovascular Society; eGFR — estimated glomerular filtration 
rate; FEV1 — forced expiratory volume in the first second; NYHA — New York Heart Association; PCI — percutaneous coronary intervention
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at 1 year, 79% vs. 64%, respectively (p = 0.026). 
Likely, a reflection of baseline clinical differences 
between the two groups i.e. patients who were 
discharged early were healthier. At 1 year, logis-
tic EuroSCORE (OR 0.973, 95% CI 0.951–0.996, 
p = 0.020), delta creatinine (OR 0.996, 95% CI 
0.992–1.000, p = 0.048) and prior pacing (OR 
2.808, 95% CI 1.122–7.011, p = 0.027) were the 
predictors of a safe outcome. 
Discussion 
Despite high risk characteristics of this patient 
group, the present data and the recently published 
works by Durand et el. [5] and Barbanti et al. [6] 
suggest that early discharge (≤ 3 days) is a feasible 
and safe option after TAVI. Factors associated with 
early discharge seem to be consistent in these 
studies and they overlap with predictors of “safe 
outcome”. Combining these factors/predictors, it 
was possible to create a protocol to facilitate early 
discharge (Fig. 2). 
One of the major concerns post-TAVI is the 
risk of potentially dangerous conduction abnormali-
ties. According to Khawaja et al. [7], the overall 
median time to permanent pacemaker implantation 
post TAVI was 4 days. However, this study looked 
at CoreValve prostheses (Medtronic, Minneapolis, 
Minnesota, USA) the use of which is associated 
with higher rates of pacing than following Edwards 
Sapien implantation. Another study utilizing both 
self-expanding and balloon-expandable TAVI valves 
has shown that pacemaker requirement becomes 
apparent at 4 days [8]. However, neither studies re-
port on the time of diagnosis of conduction defects 
post TAVI. This study indicates that early discharge 
does not increase the risk of re-admission for 
pacemaker implantation. Presumably, this suggests 
that conduction defects become evident early post 
TAVI i.e. in the first 3 days. 
The negative impact of bleeding and blood 
product transfusion on hospital stay with a va-
riety of cardiac procedures is well known and 
its influence on the TAVI patient cohort is also 
recognized. Barbanti et al. [6] demonstrated that 
lack of significant bleeding is a predictor of early 
discharge whilst Durand et al. [5] demonstrated 
that requirement of blood transfusion post-TAVI 
was a negative predictor of early discharge. The 
present group of patients was more heterogenous 
than those included in these studies and, as such, 
neither bleeding nor transfusion feature as signifi-
cant predictors of early discharge on multivariate 
analysis. Nonetheless, improving procedural tech-
niques to reduce bleeding and blood transfusion are 
likely to improve rate of early discharge. 
Table 2. Procedural characteristic.
Variable Overall Early discharge Late discharge P 
Procedure time [min] 106.64 (66.9) 101 (121) 108 (42) 0.0001
Conscious sedation 2 (0.6%) 2 (3.5%) 0 0.12
Delivery approach: 0.0001
TF-PC 111 (34.8%) 40 (71%) 71 (27%)
TF-surgical cut down 90 (28.2%) 12 (22%) 78 (30%)
TA 115 (36.1%) 4 (7%) 111 (42%)
Other 3 (0.9%) 0 3 (1%)
Sheath size [Fr] 19.97 (4) 17.4 (3.2) 20.5 (3.9) 0.0001
Valve type: 0.0001
Sapien XT 248 (77.7%) 31 (55%) 217 (82%)
Sapien 3 60 (18.8%) 20 (36%) 40 (16%)
Others 11 (3.4%) 5 (9%) 6 (2%)
Valve size [mm] 25.1 (2) 25 (1.9) 25 (2) 0.9
Pacing time [s] 50 (37) 36 (24) 53 (39) 0.0001
Volume of contrast [mL] 116 (53) 116 (52) 116 (54) 0.9
Vascular closure technique: 0.0001
Percutaneously 114 (35.7%) 41 (73%) 73 (28%)
Surgical 205 (64.3%) 15 (27%) 190 (72%)
CVA — cerebrovascular accident; TA — trans-apical; TF-PC — trans-femoral percutaneous
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Table 3. Post-procedural outcomes.
Variable Overall  
(n = 319)
Early discharge  
(n = 56)
Late discharge  
(n = 263)
P 
Early safety (at 30 days)
All-cause mortality 3 (99.1%) 0 3 (1.1%) 0.55
All stroke (includes 4 TIAs) 10 (3%) 0 10 (3.8%) 0.21
Life threatening bleeding 21 (6.5%) 0 21 (8%) 0.03
AKI stage 2 or 3 24 (7.5%) 0 24 (9%) 0.02
Coronary obstruction 0 0 0 N/A
Major vascular complications 15 (4.7%) 0 15 (5.7%) 0.08
Lack of intended performance of prosthestheic heart valve 24 (7.5%) 8 (14%) 16 (6%) 0.04
Clinical efficacy (after 30 days)
All-cause mortality 43 (13.5%) 2 (3.6%) 41 (15.6%) 0.014
All stroke 3 (1%) 1 (1.7%) 2 (0.75%) 0.99
Hospitalization for valve-related symptoms or heart failure 8 (2.5%) 2 (3.6%) 6 (2.2%) 0.63
NYHA III or IV 24 (7.5%) 2 (3.6%) 22 (8.3%) 0.27
Valve-related dysfunction 45 (14%) 6 (10.7%) 39 (14.8%) 0.52
Time-related valve safety (30 days up to a 1 year)
Valve related dysfunction 45 (14%) 6 (10.7%) 39 (14.8%) 0.52
Valve endocarditis 3 (1%) 1 (1.7%) 2 (0.8%) 0.99
Valve thrombosis 0 0 0 N/A
Thrombo-embolic events* 3 (1%) 1 (1.7%) 2 (0.75%) 0.99
VARC bleeding$ 0 0 0 N/A
Outcomes that are not captured by VARC-2
Level two stay [day] 1.34 (1.6) 0.93 (0.68) 1.43 (1.8) 0.0001
Delta creatinine 27 (72) -3 (13) 33 (77) 0.0001
Haemoglobin drop 26 (16) 21 (11) 27 (17) 0.0001
Blood transfusion 80 (25%) 3 (5%) 77 (29%) 0.0001
GI bleed 2 (0.6%) 0 2 (0.6%) 1
*Based on stroke events. $ There were three cases of upper gastrointestinal bleeds that were not related to transcatheter aortic valve replace-
ment (TAVI); GI — gastro-intestinal, creatinine (umol/L), hemoglobin (g/L); AKI — acute kidney injury; N/A — not applicable; NYHA — New 
York Heart Association; VARC-2 — Valve Academic Research Consortium-2; TIA — transient ischemic attack
The predictive value associated with serum 
creatinine seems consistent in this study and 
others [5, 6]. AKI post-TAVI is associated with 
increased mortality [9] but studies on outcome 
post-TAVI and chronic kidney disease have shown 
inconsistent results [10, 11] thus far. The influence 
of these conditions on hospital stay has not been 
studied in detail. The reported OR on post-TAVI 
delta creatinine demonstrates clearly that AKI has 
a negative impact on early discharge rates. 
The occurrence of any complication influence 
discharge. It is noteworthy that Durand et al. [5] 
showed that most of the major complications post 
TAVI occurred within 48 h after the procedure i.e. 
patients who developed complications were known 
by day three and therefore not discharged. The 
study also reports that only 3 patients had delayed 
major complications. 
Based on current evidence, factors associated 
with early discharge are therefore prior pacemaker 
(OR 2.27–2.8), and a more recently performed 
procedure (a reflection of the advancement of the 
technique, OR 1.66), NYHA IV (OR 0.22), logistic 
EuroSCORE (OR 0.94), bleeding (OR 0.31), trans-
fusion (OR 0.10), previous balloon aortic valvulo-
plasty (OR 0.44), delta creatinine (OR 0.96–0.99), 
and developing a complication (OR 0.17). 
This study demonstrates that clinically se-
lected early discharge is associated with similar all-
cause re-admission rate, similar 30-day mortality 
and similar re-admission rate for permanent pacing. 
These findings are consistent with other published 
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Table 4. Univariate and multivariate predictors of early discharge.
Variable Odds ratio 95% CI P
Univariate analysis
Sex 1.08 0.608–1.908 0.788
Age 0.992 0.960–1.024 0.619
Body mass index 1.024 0.995–1.055 0.110
Logistic EuroSCORE 0.949 0.918–0.981 0.002
Diabetes mellitus 0.926 0.437–1.961 0.841
Hypertension 0.895 0.450–1.779 0.751
Creatinine pre-TAVR 0.995 0.987–0.1002 0.166
NYHA III/IV 0.476 0.266 –0.853 0.013
Previous MI 2.205 0.862–5.643 0.099
PVD 2.176 0.981–4.828 0.056
EF < 30% 2.490 0.723–8.582 0.148
Paced pre-TAVR 0.622 0.276–1.404 0.253
AV mean gradient 0.980 0.958–1.001 0.065
Procedure time 0.998 0.991–1.004 0.525
Delta creatinine 0.973 0.959–0.987 0.001
Hemoglobin drop [g/L] 0.975 0.957–0.994 0.009
Blood transfusion 0.137 0.041–0.451 0.001
Life-threatening bleed 0.233 0.031–1.781 0.161
Any complication 0.141 0.049–0.401 0.001
Multivariate analysis
Logistic EuroSCORE 0.947 0.912–0.983 0.004
NYHA III/IV 0.748 0.375–1.491 0.410
Paced pre-TAVI 0.967 0.645–4.338 0.290
Delta creatinine 0.967 0.949–0.985 0.001
Any complication 0.174 0.048–0.630 0.008
Life-threatening bleed 1.777 0.151–20.967 0.648
Blood transfusion 0.429 0.119–1.554 0.198
AV — aortic valve; CI — confidence interval; EF — ejection fraction; MI — myocardial infarction; NYHA — New York Heart Association;  
PVD — peripheral vascular disease; TAVI — trancatheter aortic valve implantation
studies [5, 6]. It also shows that early discharge is 
associated with a safe outcome for up to 1 year. The 
current trend in practice towards conscious seda-
tion may influence the early discharge rate further; 
nonetheless, the present experience shows safe 
early discharge even for those performed under 
general anaesthesia. Overlap between factors 
associated with early discharge and predictors of 
safe outcome provides us with an opportunity to 
devise a clinical protocol that incorporates these 
predictors (Fig. 2). 
Safe early discharge is likely to significantly 
improve cost-effectiveness of TAVI. Babaliaros 
et al. [12], as demonstrated previously, that with 
a ‘minimalist approach’ with TF TAVI, shorter 
length of stay translated into lower resource use 
and significantly lower hospital costs. The same is 
likely to apply to early discharge. 
This is a retrospective observational study 
with the inherent limitations of any observational 
study. Physical performance status and family sup-
port are significant confounders of early discharge 
among the elderly TAVI patients. Assessment of 
frailty and quality of life was introduced recently 
into the TAVI practice and as such quantifying 
these important social issues in retrospect is dif-
ficult and was not included in the analysis. 
All patients included who received this tech-
nology throughout its evolution and practice has 
changed significantly. It is well known that the 
TAVI procedure in the current era is significantly 
different from 2007 and as such it is appreciated 
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Table 5. List of causes of re-admissions.
30-day re-admissions 12-month re-admissions
Cardiovascular Non-cardiovascular Cardiovascular Non-cardiovascular
Bilateral groin hematomas 
needing IV antibiotics
Right femoral pseudo- 
-aneurysm needing thrombin
Right femoral pseudo- 
-aneurysm
Left pleural effusion  
(conservative management)
Left pleural effusion requiring  
a chest drain
Groin Seroma
Fluid overload needing  
IV diuretics (2 cases)
Groin swelling (3 cases)
Fast AF and CCF
Elective admission for EVAR
LRTI (2 cases)
Fall
‘Not coping at home’
Pneumonia with pleural 
effusion needing a chest 
drain
Sepsis
Syncope with bi-fascicular 
block needing a PPM
Non cardiac chest pain  
(2 cases)
Repair of femoral pseudo-
aneurysm (TAVI complica-
tion, 2 cases)
Elective admission for  
right femoral AVF  
exploration and wound 
debridement (TAVI  
complication)
Post-operative external 
apical clot (echocardio-
graphy surveillance)
Infected groin wound 
needing IV antibiotics
Exercise induced cerebral 
hypo-perfusion due to 
bilateral carotid artery 
stenosis
Investigation for stroke  
(no evidence of stroke)
CRT upgrade
Dyspnea due to CCF  
(4 cases)
TAVI groin wound  
infection
Chest pain at rest needing 
LAD-PCI (2 cases)
Investigation for IE (no  
evidence of IE) (2 cases)
Worsening dyspnea due to 
pulmonary hypertension 
TIA
IE of TAVI (2 cases)
Atrial tachycardia with 
poor tolerance
Elective admission for  
AF ablation
Stroke (2 cases)
AF and heart failure post-
TAVI complicated with IE
Elective for CRT-P (2 cases)
Ischemic large leg ulcer
Elective admission for EVAR
Pseudoanuerysm
Sternal wall exploration
Worsening gradient  
needing re-do TAVI
Unstable angina
Renal artery stenosis  
requiring intervention
Falls (2 cases)
Urology admission for  
flexible cystoscopy (2 cases)
Pelvic fracture
Readmission for OGD.  
Had UGI bleed post TAVI
Elective CEA
Ophthalmology (2 cases)
Hyperkalaemia secondary 
to medications and  
ineffective dialysis line
Confusion
Syncope due to recurrent 
pneumothorax and  
postural hypotension
Dyspnea due to idiopathic 
anemia
Non-cardiac dyspnea
Acute confusion needing 
intubation
UGI bleed (3 cases)
Closed loop bowel  
obstruction in a back-
ground of internal hernia
Fall
Septic shock with MOF
Pulmonary embolism  
(2 cases)
Hematology admission
ERCP
Confusion
Hemoptysis (negative 
bronchoscopy) 
COPD exacerbation (2 cases)
Total hip replacement  
(2 cases)
Urinary retention
Heat stroke
Mixed dementia
AF — atrial fibrillation; AVF — arteriovenous fistula; CCF — congestive cardiac failure; CEA — carotid endarterectomy; COPD — chronic  
obstructive pulmonary disease; CRT — cardiac resynchronization therapy; ERCP — endoscopic retrograde cholangiopancreatography;  
EVAR — endovascular aneurysm repair; IE — infective endocarditis IV — intravenous; LRTI — lower respiratory tract infection; LAD-PCI — left 
anterior descending percutaneous coronary intervention; MOF — multi-organ failure; MSK — musculoskeletal; OGD — oesophago-gastro 
duodenoscopy; PE — pulmonary embolism; PPM — permanent pacemaker; TAVI — transcatheter aortic valve implantation; TIA — transient 
ischemic attack; UGI — upper gastrointestinal
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that this group of patients is heterogenous. None-
theless, our center has evolved with the technique 
and offers an experience across these develop-
ments in both device technology and practical 
experience. Finally, the present results may not 
apply to other prostheses knowing that this was 
primarily an Edwards Sapien centre. 
Conclusions
Lower logistic EuroSCORE, smaller delta cre-
atinine and not developing any complication were 
factors associated with early discharge. Moreover, 
the presented data confirm that early discharge 
post TAVI is feasible, safe and likely to improve 
cost-efficiency. Efforts to preserve renal function 
and avoid bleeding peri-procedurally are likely the 
two main modifiable predictors of early discharge. 
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